Tag: PhD5

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More

Poster-Disease-modifying Therapy

Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study

Background: Patients with relapsing-remitting multiple sclerosis (RRMS) often experience disease activity despite receiving a...

Read More

Poster-Disease-modifying Therapy

Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies

Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...

Read More

Poster-Disease-modifying Therapy

Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...

Read More

Platform-Neuroimaging

Accurate Cervical Spinal Cord Area Measurements Can be Extracted from Brain Images

Background: Multiple Sclerosis (MS) is an inflammatory, demyelinating disease with neurodegeneration in the central nervous system. Spinal...

Read More

Platform-Disease Modifying Therapies

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...

Read More

Platform-Disease Management

Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial

Background: Black, African American (AA) and Hispanic/Latino (HA) patients with multiple sclerosis (MS) have greater disease severity and...

Read More

Platform-Disease Modifying Therapies

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...

Read More

Platform-Psychosocial

Health-Related Quality of Life across the Lifespan in Persons with Multiple Sclerosis and Healthy Controls

Background: Health-related quality of life (HRQOL) is reduced in persons with multiple sclerosis (MS) compared with the general population,...

Read More